Adnkronos Rome, October 10 (Adnkronos Salute) – "Cardiology has been a cutting edge for decades, but it has been overtaken by other branches of medicine, such as hematology, oncology, and rheumatology, which have made great strides in personalizing research and treatment to the individual patient." This was stated by Michele Senni, director of Cardiology 1 and the Cardiovascular Department at Papa XXIII Hospital in Bergamo and professor of Cardiology at Milan-Bicocca University, in his speech yesterday in Rome at the Investigator's Meeting, which focused on various areas of clinical research conducted by AstraZeneca in Italy, involving over 160 clinicians.
"Cardiovascular diseases have a significant impact on patients' lives," Senni emphasized. "Clinical research allows us to extend and improve patients' lives. It also acts as a powerful driver of healthcare advancement, improving the quality of care. It's a significant incentive for the professionals who work in these facilities." Senni, however, believes research requires synergy between the public, private, and pharmaceutical sectors: "I believe collaboration between healthcare professionals and pharmaceutical companies is essential. Pharmaceutical companies," he explained, "allow us to conduct research that would be difficult for individual facilities to sustain, even those in public research. On the other hand, the healthcare system can ensure the network of hospitals and clinics that provide access to patients on whom new drugs are tested."